Scientific Advisory Board
Protagen’s international scientific advisory board brings together key opinion leaders from both the immuno-oncology and autoimmune disease fields.
In collaboration with its expert panels, Protagen benefits from industry-leading expertise, allowing for the development of precision diagnostic solutions that address the immuno-oncology and autoimmune disease markets’ needs.
Contact us to find out more about how Protagen is helping to drive the discovery of effective therapies for immuno-oncology and autoimmune disease.
Dr Jessica Hassel
Jessica Hassel is the head of the Section of DermatoOncology of the Department of Dermatology in the National Center for Tumor Diseases (NCT) in Heidelberg, Germany. She is a dermatologist by training and received additional board certifications for medicinal tumor therapy, dermatopathology and palliative medicine. Scientifically she worked at the German Cancer Research Center Heidelberg with a focus on translational oncology and received the Venia Legendi of the University of Heidelberg in 2016. Since 2010 she has established an internationally renowned clinical trial center for patients with metastasized skin tumors (especially melanoma) at the NCT. She received the German Skin Cancer Award in 2018.
Dr Aurélien Marabelle
Aurélien Marabelle is the Clinical Director of the Cancer Immunotherapy Program at Gustave Roussy Cancer Center in Villejuif, France. Dr Marabelle’s clinical practice is dedicated to Early Phase Clinical trials in Cancer Immunotherapy and his translational research is focused on mechanisms of action of immune checkpoint monoclonal antibodies. He works as a senior medical oncologist and an investigator in the Drug Development Department (DITEP) directed by Professor Jean-Charles Soria. He is coordinating a team focusing on cancer immunotherapy translational research projects in the INSERM U1015 lab directed by Professor Laurence Zitvogel. Dr. Marabelle is a member of ESMO, ASCO, EATI and AACR.
Professor Vibeke Strand
Vibeke Strand is a consultant in clinical research and regulatory affairs for pharmaceutical and biotech companies. She has been a clinical rheumatologist for 35 years in a sub-specialty practice in San Francisco as a clinical investigator, and subsequently as Director of Clinical Research at three pharmaceutical and biotech companies, prior to establishing her consulting practice in 1991. She is a member of the clinical faculty at Stanford University, serving as Adjunct Clinical Professor (Division of Immunology and Rheumatology) since September 2000, Clinical Associate Professor since 1993 and has held positions at the University of California, San Francisco.
Professor Matthias Schneider
Matthias Schneider is Head of the Rheumatology Clinic at the Hiller Research Unit at Heinrich-Heine-University, Duesseldorf and Rhein-Ruhr, The Cooperation Multipurpose Arthritis Center. He is qualified within internal medicine, rheumatology, physical therapy and endocrinology and has been working in this field for more than 30 years. In 1988, he was awarded Venia Legendi for Internal Medicine. From 2013–2014, he was President of the German Society of Rheumatology, and he represented German rheumatology research in The European League Against Rheumatism (EULAR) recommendations for various topics in systemic lupus erythematosus (SLE). For more than 20 years he supported the German SLE patient group as a board member and has been a medical advisor of Lupus Europe since 2004.
Protagen’s corporate leadership team combines over 40 years of commercial expertise and experience within the biotechnology industry, with a background spanning immunology, oncology, biomarker discovery and more.
Protagen is dedicated to the development of powerful diagnostic tools that aid successful therapeutic development and facilitate improved treatment strategies in the areas of autoimmune disease and immuno-oncology.
Protagen has a number of established and committed investors, but is always looking at entering into new partnerships to help progress its research and commercialization efforts. If you are interested in investing in the company, please contact us.
Here you will find our quarterly newsletter, “Stratified News from Dortmund”. With our newsletter we intend to regularly update you on developments at Protagen in a fresh and colorful format and we hope that you like it.
Get in touch
Improving the treatment of cancer and autoimmune disease is our passion, and we always welcome the chance to discuss these topics with current and prospective customers, patients and clinicians alike.